1,141 Shares in Guardant Health, Inc. (NASDAQ:GH) Bought by JNBA Financial Advisors

JNBA Financial Advisors purchased a new stake in Guardant Health, Inc. (NASDAQ:GH) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 1,141 shares of the company’s stock, valued at approximately $26,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Quarry LP bought a new position in shares of Guardant Health during the 2nd quarter worth approximately $44,000. Canton Hathaway LLC acquired a new stake in Guardant Health during the 2nd quarter valued at $59,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Guardant Health during the second quarter worth $71,000. Byrne Asset Management LLC acquired a new position in shares of Guardant Health in the second quarter valued at $77,000. Finally, Manchester Capital Management LLC bought a new position in shares of Guardant Health in the first quarter valued at about $57,000. Institutional investors own 92.60% of the company’s stock.

Guardant Health Trading Up 7.5 %

Shares of GH stock opened at $25.29 on Thursday. Guardant Health, Inc. has a fifty-two week low of $15.81 and a fifty-two week high of $37.04. The stock’s fifty day moving average price is $23.02 and its two-hundred day moving average price is $25.88. The company has a debt-to-equity ratio of 16.70, a quick ratio of 6.07 and a current ratio of 6.40. The company has a market cap of $3.11 billion, a PE ratio of -6.18 and a beta of 1.11.

Guardant Health (NASDAQ:GH) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.10). The business had revenue of $177.24 million during the quarter, compared to analyst estimates of $162.59 million. Guardant Health had a negative net margin of 76.23% and a negative return on equity of 418.21%. The business’s quarterly revenue was up 29.2% compared to the same quarter last year. During the same period last year, the business earned ($0.67) earnings per share. Equities analysts predict that Guardant Health, Inc. will post -3.31 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

GH has been the topic of several research reports. Bank of America upped their target price on Guardant Health from $28.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, July 18th. Craig Hallum increased their price objective on Guardant Health from $28.00 to $37.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. Sanford C. Bernstein dropped their target price on Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a report on Wednesday, October 30th. BTIG Research upped their price target on shares of Guardant Health from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, July 30th. Finally, Citigroup raised their price target on shares of Guardant Health from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. One equities research analyst has rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $40.00.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.